Home » Stocks » Menlo Therapeutics

Menlo Therapeutics Inc. (MNLO)

Stock Price: $1.60 USD -0.03 (-1.54%)
Updated Jul 16, 2020 10:59 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 267.36M
Revenue (ttm) 1.89M
Net Income (ttm) -95.06M
Shares Out 167.62M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $1.60
Previous Close $1.62
Change ($) -0.03
Change (%) -1.54%
Day's Open 1.61
Day's Range 1.55 - 1.62
Day's Volume 663,108
52-Week Range 1.00 - 7.48

More Stats

Market Cap 267.36M
Enterprise Value 219.24M
Earnings Date (est) Jul 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 167.62M
Float 114.90M
EPS (basic) -3.23
EPS (diluted) -2.01
FCF / Share -2.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.24M
Short Ratio 1.62
Short % of Float 7.87%
Beta 1.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 141.83
PB Ratio 3.78
Revenue 1.89M
Operating Income -96.46M
Net Income -95.06M
Free Cash Flow -99.29M
Net Cash 48.11M
Net Cash / Share 0.29
Gross Margin 23.50%
Operating Margin -5,117.29%
Profit Margin -5,432.20%
FCF Margin -5,267.37%
ROA -54.07%
ROE -162.96%
ROIC -182.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.56*
(311.29% upside)
Low
2.50
Current: 1.60
High
15.00
Target: 6.56
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-10.644.580.67-
Revenue Growth-132.21%579.82%--
Gross Profit-10.644.580.67-
Operating Income-76.24-54.54-29.59-14.33-4.61
Net Income-73.70-51.45-29.08-14.07-4.61
Shares Outstanding23.8221.675.114.994.74
Earnings Per Share-3.09-2.37-5.69-2.82-0.97
Operating Cash Flow-65.10-52.73-28.22-2.27-4.18
Capital Expenditures-0.01-0.14-0.03-0.03-
Free Cash Flow-65.11-52.87-28.25-2.30-4.18
Cash & Equivalents73.3713659.5030.9143.81
Total Debt34.47----
Net Cash / Debt38.9013659.5030.9143.81
Assets81.1614066.8742.0543.89
Liabilities63.589.5514.5712.490.84
Book Value17.58130-57.03-29.44-15.95
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Menlo Therapeutics Inc.
Country United States
Employees 180
CEO David Domzalski

Stock Information

Ticker Symbol MNLO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MNLO
IPO Date January 25, 2018

Description

Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey.